We recently compiled a list of 10 High Growth NASDAQ Stocks That Are Profitable in 2024. In this article, we will look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the high-growth NASDAQ stocks that are profitable.

Will the Bull Market Continue as We Enter the Earnings Season?

Malcolm Ethridge, Capital Area Planning Group managing partner, joined CNBC to talk about where the market could go and his sentiment regarding the AI and overall tech sector. While many analysts believe that it will be the small caps that will lead the growth with interest rates easing and the economy slowing down. We recently covered the 8 Most Undervalued Penny Stocks To Buy According To Analysts, where we talked about how Tom Lee, co-founder of Fundstrat Global Advisors likes the small cap in the current market environment. Here’s a piece from the article:

“To talk about what the stock market looks like today and in the near future. Tom Lee, co-founder of Fundstrat Global Advisors joined CNBC in a recent interview. He has been one of the strong proponents and supporters of small-cap stocks. Lee says that we are in a volatile environment currently, due to a few reasons, one being the elections in less than 30 days, the second being the Middle Eastern crisis which is scaring investors, and lastly the port strike that has the potential to cripple the economy. However, he still expressed his optimism that the year-end has a lot of tailwinds and investors shouldn’t be afraid to buy the dip. Moreover, Lee also highlighted that these current events are all short-term headwinds in a buying cycle and are expected to die down quickly.

Lee thinks that bottoms are tough and processed, and small caps are in the process of what could be a multi-year bottom. Therefore the conviction is that some people might want to buy the big names on NASDAQ and the AI market, however, with small caps trading at lower multiples of P/E less than 10, the risk and reward lie in small caps. Lee further mentioned that interest rate cuts and better earnings growth make the path for small-cap growth more visible.

Tom Lee has also reaffirmed his belief that the S&P 500 could close above 5,700 by year-end, supported by strong economic fundamentals and a dovish Federal Reserve beginning to cut interest rates. He noted that significant cash reserves are available for investment, which could drive stock prices higher in the next three to twelve months.”

Ethridge thinks otherwise, he believes that mega-cap stocks will continue to lead market growth, although not at the same pace as in recent years but still at a steady pace. He attributes this to the ongoing influence of artificial intelligence (AI) on various sectors, including real estate and manufacturing, which are becoming increasingly vital due to rising demands on infrastructure.

Moreover, while explaining why the mega caps will lead the growth, Ethridge pointed out that for the big tech stocks, Fed rate cuts were not necessary as they had significant cash on their balance sheets to reinvest into newer AI ventures. We have already seen Magnificent Seven invest heavily in AI despite the high rate of borrowing thereby leading the bull market in difficult times.

The rate cuts have now made it easy for other companies that didn’t have enough cash to borrow and invest in technology. However, he also pointed out that the pace of rate cuts might slow down moving forward, thereby making it hard for small caps to keep up the technology investment race. Ethridge suggests that investors may need to adjust their expectations regarding future Federal Reserve rate cuts.

Moreover, we are also entering earnings season, will the earnings derail the momentum or continue to boost the market? Drew Pettit, Citi Research Director of US Equity Strategy joined CNBC in another interview. He thinks that we are in for a decent quarter, although we are in an expensive market.

While talking about how various sectors will perform, Pettit mentioned that software has the highest bar within tech, meaning its growth expectations are high, yet many software companies are not monetizing effectively. This creates volatility in stock performance. As earnings reports come in, Pettit suggests investors should focus on consumer behavior and credit conditions, particularly in the banking sector, which is expected to perform well this quarter. He also encouraged investors to look beyond the recent quarter earnings into 2025 and 2026, while choosing companies to invest in.

Our Methodology

To curate the list of 10 high-growth NASDAQ stocks that are profitable in 2024 we used the Finviz stock screener, Seeking Alpha, and Yahoo Finance as our sources. Using the stock screener, we got an initial list of major NASDAQ stocks sorted by their market capitalization. Next, we sourced the 5-year net income growth and revenue growth rates for these stocks from Seeking Alpha and the GAAP trailing twelve-month net income from Yahoo Finance. We only selected stocks that had 5-year net income and revenue growth of more than 15%. Lastly, we ranked the stocks by the number of hedge fund holders in Q2 2024 from Insider Monkey’s database. The list is ranked in ascending order of the number of hedge fund holders.

Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

5-Year Net Income Growth: 15.87%

5-Year Revenue Growth: 15.57%

TTM Net Income: $4.32 Billion

Number of Hedge Fund Holders: 57

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is another biotechnology company that ranks 8th on our list of high-growth NASDAQ stocks that are profitable in 2024. It engages in the development of new drug treatments aimed at treating various diseases, including cancer, eye diseases, and allergic conditions.

Medicines including EYLEA, Dupixent, Librato, and Praluent are some leading first treatment medicines for the company driving considerable revenue. Moreover, the drug development methods employed by Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) set it apart from its competitors. It uses AI to speed up the process of drug discovery and development. Its Regeneron Genetics Center is an AI-driven genetic research center that has one of the world’s largest genetic research databases which is used in developing new treatments.

Despite these strategic edges, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) recently came under some competitive pressure when one of its competitors developed a biosimilar medicine to EYLEA, which treats an eye disease called wet age-related macular degeneration (AMD). The company has filed a lawsuit against the FDA approval for this biosimilar medicine but the trial is yet to begin. This has scared away some investors.

However, here’s what you might not know about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN). EYLEA still has an edge over this competitor as the high-dose version of the medicine allows patients to treat the disease in less doses thereby becoming one of the key selling points for the company. Moreover, in the second quarter sales of EYLEA and EYLEA HD came in with a 2% increase year-over-year to $1.53 billion. The overall revenue of the company was $3.55 billion, up 12% during the same time.

Another point of relief for investors is that EYLEA is not the main growth driver for the company. Eczema treatment Dupixent is one of the key drivers of growth for the company and its sales grew 27% year over year to $3.56 billion indicating that even if the lawsuits goes south the growth engines will continue firing. Moreover, the company has some 50 programs in the pipeline which advocate for continued growth of the company.

Bronte Capital Amalthea Fund made the following comment about Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in its Q3 2023 investor letter:

“In the last quarterly letter, we discussed the problems in our long book. These were:

a) companies that sell technical products to improve the conversion of grain into meat (such as animal genetics and feed additives), and

b) Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), which had received a “Complete Response Letter” (an FDA rejection) for their new longer-lasting wet age-related macular degeneration drug.

The first of these problems has persisted. Grain prices remain high relative to meat prices and the stocks in question have followed their quality European peers down. The two losers in this sector are Genus and DSM-Firmenich…” (Click here to read the full text)

Overall REGN ranks 8th on our list of the high-growth NASDAQ stocks that are profitable. While we acknowledge the potential of REGN as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for a promising AI stock that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.

Disclosure. None. This article was originally published on Insider Monkey.